Similar articles

• [New drug approvals over three decades from 1980 to 2009 in Japan--their therapeutic targets and biochemical properties].

  Muramatsu M, Arisue Y. Muramatsu M, et al. Yakugaku Zasshi. 2011 Apr;131(4):603-19. doi: 10.1248/yakushi.131.603. Yakugaku Zasshi. 2011. PMID: 21467801 Japanese.
• Tuberculosis treatment for the beginning of the next century.

  Schraufnagel DE. Schraufnagel DE. Int J Tuberc Lung Dis. 1999 Aug;3(8):651-62. Int J Tuberc Lung Dis. 1999. PMID: 10460097 Review.
• [Methodological considerations in the design of clinical trial for innovative hepatitis B drugs].

  Kong YY, Liu XQ, You H, Jia JD, Hu B, Chow XZ, Yao C. Kong YY, et al. Zhonghua Gan Zang Bing Za Zhi. 2020 Aug 20;28(8):658-661. doi: 10.3760/cma.j.cn501113-20200722-00413. Zhonghua Gan Zang Bing Za Zhi. 2020. PMID: 32911903 Chinese.
• The year's new drugs and biologics 2018: Part I.

  Graul AI, Pina P, Cruces E, Stringer M. Graul AI, et al. Drugs Today (Barc). 2019 Jan;55(1):35-87. doi: 10.1358/dot.2019.55.1.2959663. Drugs Today (Barc). 2019. PMID: 30740611
• Therapeutic monitoring of the new antiepileptic drugs.

  Tomson T, Johannessen SI. Tomson T, et al. Eur J Clin Pharmacol. 2000 Jan;55(10):697-705. doi: 10.1007/s002280050001. Eur J Clin Pharmacol. 2000. PMID: 10663446 Review.